Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Accounts Payables · Q4 FY2026 · quarter ended Sep 2026
Accounts payables turns positive
Q4 FY2026 accounts payables was $2.5M, compared with -$15.38M a year earlier. Trailing-twelve-month accounts payables was $14.67M. Over 3 fiscal years it compounded at -27.7% a year.
Context
- Accounts payables amounted to 2.8% of revenue in FY2026, up 2.0 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $2.5M or moves back toward the trailing-twelve-month quarterly average of $3.67M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2026
- 12.48M USD
- Year-over-year change
- +98.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 12.48M | +98.5% |
| FY2025 | 2025-09-30 | 6.29M | +213.5% |
| FY2024 | 2024-09-30 | (5.54M) | -116.8% |
| FY2023 | 2023-09-30 | 33M | +600.8% |
| FY2022 | 2022-09-30 | (6.59M) | — |
Accounts Payables vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +133.3% is the highest of 5, against a peer median of -46.4%.
- Accounts payables amounts to 3.3% of revenue for ARWR, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.76M USD | -237.3% | -26.8% | 1.4% | |
| LTM Sep 2026 | $14.67M USD | +133.3% | -27.7% | 3.3% | |
| LTM Sep 2026 | $11.71M USD | -66.8% | — | 1.2% | |
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $4.81M USD | +99.3% | — | 6.7% | |
| LTM Mar 2026 | $2.19M USD | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding ARWR) | — | -46.4% | -14.3% | 3.1% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | (176.49M) | (209.28M) | (609.69M) | 30.11M | (717.13M) |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 120.89M | 78.13M | 73.97M | 63.37M | 68.15M |
| Change in Working Capital | (98.29M) | (51.55M) | 25.09M | (18.24M) | 60.9M |
| Accounts Receivables | 8.85M | 1.41M | 0 | (56.97M) | (3.29M) |
| Inventory | 0 | 0 | 0 | 0 | (9.08M) |
| Accounts Payables | (6.59M) | 33M | (5.54M) | 6.29M | 12.48M |
| Other Working Capital | (100.55M) | (85.96M) | 30.63M | 32.45M | 60.78M |
| Other Non-Cash Items | 7.34M | 16.31M | 29.19M | 80.38M | 289.52M |
| Operating Cash Flow | (136.13M) | (153.89M) | (462.85M) | 179.55M | (271.95M) |
| Capital Expenditures | (52.78M) | (176.74M) | (141.47M) | (22.67M) | (12M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (223.39M) | (246.14M) | (720.95M) | (796.26M) | (1.14B) |
| Sales of Investments | 270.75M | 326.72M | 442.34M | 689.63M | 695.23M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (215M) |
| Investing Cash Flow | (5.42M) | (96.16M) | (420.07M) | (129.29M) | (670.48M) |
| Debt Repayment | 0 | 0 | 392M | (191.37M) | 578.52M |
| Common Stock Issued | 5.19M | 3.05M | 431.65M | 270.37M | 305.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | 250M | 46.87M | (5M) | (107.12M) |
| Financing Cash Flow | 65.19M | 253.05M | 870.52M | 74.01M | 776.82M |
| Effect of Forex Changes | (67K) | (122K) | 4.2M | (401K) | 1.8M |
| Net Change in Cash | (76.43M) | 2.89M | (8.21M) | 123.86M | (163.81M) |
| Free Cash Flow | (188.91M) | (330.63M) | (604.32M) | 156.89M | (283.94M) |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.